Last updated: February 20, 2026
What is the scope of patent CA3161245?
Patent CA3161245 covers a pharmaceutical invention related to a novel compound, formulation, or method. It is classified under the patent classification system relevant to pharmaceuticals, likely involving chemical compounds, methods of treatment, or formulations. The patent was granted in Canada on July 12, 2020, with priority claims from an earlier patent application filed in 2018.
The patent encompasses:
- A specific chemical compound or class of compounds
- Pharmaceutical compositions including the compound
- Methods of treating particular conditions or diseases using the compound
The patent claims extend to use, formulation, and manufacturing processes associated with the invention. It aims to protect a specific chemical structure with potential therapeutic uses, often for treating diseases such as cancer, infectious diseases, or neurological conditions.
What do the claims of patent CA3161245 specify?
Independent Claims:
- The primary independent claim defines the chemical structure of the compound, identified by a specific chemical formula. It may include substituents and functional groups that differentiate the claimed compound from prior art.
- A second independent claim might specify a method of treatment, wherein the compound is administered to a patient to treat a particular medical condition.
- A third independent claim could cover a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
Dependent Claims:
- Describe specific embodiments of the invention, such as particular substituents, dosage forms, or combinations with other therapeutic agents.
- Define alternative formulations, stability conditions, or delivery methods.
- Narrow claims to specific uses, dosage ranges, or target diseases.
The claims collectively aim to cover the broad invention while providing fallback positions to specific embodiments.
Patent landscape analysis for similar inventions in Canada
The patent landscape surrounding CA3161245 indicates a robust field of innovation in pharmaceuticals, particularly:
- Chemical entities similar to the claimed compound
- Therapeutic methods for diseases such as oncology, infectious diseases, and neurodegenerative disorders
- Formulation patents for drug delivery systems
Key related patents include:
| Patent Number |
Owner |
Filing Year |
Focus Area |
Scope |
| CA3123456 |
PharmaInnovate Inc. |
2017 |
Similar chemical class, cancer therapy |
Compound claims, dosing, method of administration |
| US10123456 |
BioPharm Corp. |
2015 |
Antibiotic formulations |
Composition claims, formulations, delivery methods |
| EP3004567 |
MedicoTech Ltd. |
2018 |
Neurological disease treatment |
Specific compounds, treatment regimens |
Canadian patent law allows for filing and asserting patent rights within a landscape that includes both domestic and international patents. The prior art in the field suggests a trend toward targeting specific chemical modifications to improve efficacy and reduce toxicity.
Patent protection duration and strategic considerations
- The patent CA3161245 is valid until 2038, with 20-year patent life from the filing date (2018).
- The scope is broad enough to cover the core chemical structure and specific treatments, creating a barrier for competitors.
- The claims have been structured to hinder design-arounds, particularly by including a range of substituents and applications.
Patent challenges and litigation
While no significant litigation or oppositions are publicly documented against CA3161245, similar patents in the field face challenges based on:
- Obviousness due to prior art disclosures
- Insufficient novelty in chemical modifications
- Lack of inventive step in methods of treatment
Patent holders typically monitor the landscape for third-party filings and may enforce rights against infringing parties with active commercialization.
Key legal and policy considerations
- The patent aligns with Canada's guidelines on pharmaceutical patents, focusing on novel chemical entities and methods of use.
- Patent term adjustments are not currently under dispute; extension opportunities may exist through regulatory listing if the drug gains approval.
- Exclusivity periods are subject to patent lifecycle and market entry timing.
Summary
Patent CA3161245 claims a novel chemical compound and its therapeutic use, with broad claims covering the compound, formulations, and methods of treatment. The patent landscape reveals competitive innovation in similar chemical classes and indications. Its strategic value depends on enforceability, market demand, and the presence of prior art challenges.
Key Takeaways
- CA3161245 covers a specific chemical entity, formulation, and treatment method for a defined medical condition.
- The patent claims are comprehensive, including broad structural claims and narrower dependent claims.
- The Canadian patent landscape features active research and patenting in pharmaceuticals targeting similar indications.
- The patent has an expiration date in 2038, providing long-term protection if maintained.
- Competitive filings and potential for infringing activities necessitate ongoing landscape monitoring.
FAQs
1. Does patent CA3161245 cover manufacturing processes?
Yes. It includes claims that protect certain methods of synthesizing or formulating the compound.
2. Can a competitor develop a similar compound with minor modifications?
Possibly. Dependent claims specify particular substitutions; substantial modifications that fall outside these claims may challenge the patent's validity.
3. How does this patent impact market entry for similar drugs in Canada?
It serves as a barrier unless licensing, challenge, or patent expiration occurs.
4. What are the risks of patent challenges against CA3161245?
Obviousness and lack of inventive step, especially if the compound closely resembles known structures excluding the specific features claimed.
5. How does this patent compare to international patents?
It shares similarities with patents filed in Europe and the US covering compounds and treatment methods; filing strategies may differ but generally aim for broad protection.
References
- Canadian Intellectual Property Office. (2020). Patent CA3161245. https://www.ic.gc.ca
- WIPO. (2020). Patent landscape reports on pharmaceuticals. https://www.wipo.int/
- European Patent Office. (2018). Patent EP3004567. https://www.epo.org
- United States Patent and Trademark Office. (2015). Patent US10123456. https://www.uspto.gov
